InvestorsHub Logo
Followers 155
Posts 2695
Boards Moderated 0
Alias Born 01/29/2004

Re: georgejjl post# 368731

Tuesday, 08/02/2022 10:02:41 AM

Tuesday, August 02, 2022 10:02:41 AM

Post# of 473845
Once Again, 3-71 Succeeds

https://79bcf7a1-8b8e-483b-b7cf-f5c5192a6d63.usrfiles.com/ugd/79bcf7_ebfbe5fa6e924647a3272c209977cbe5.pdf?mc_cid=314a22ea6e&mc_eid=39975e48cc

--- The impairment in Tg rats was completely reversed with ANAVEX®3-71 (p ≤ 0.01).

--- ANAVEX®3-71-treated Tg rats performed significantly better than Tg control rats (p ≤ 0.05).

--- This deficit in Tg rats was entirely reversed with ANAVEX®3-71 (p ≤ 0.0001).


Read the data for yourself; unless, of course, you are certain that the effects of a drug acting in a transgenic rat can't possibly reveal how the drug would work in a real human with the same disease genetics. No need to go further. Mice aren't men; rats with human disease genes inserted in them can't possibly predict how a drug targeted at the disease will work in humans. Rats and people both breathe air and utilize oxygen to take up de-energized hydrogens and produce water in cellular respiration. But, beyond that, rats aren't people and human drug studies in them cannot be predictive.

OR, rats and humans, as mammals, have very parallel chemistries and genomics, so if human disease genes (as, in this case, for Alzheimer's) are inserted (gene editing) in a rat, the rat actually gets the disease with all of its human symptoms. Then, a drug is tested in the transgenic rats, to see if it yields any therapeutic benefits. In this case, symptoms were "completely reversed," diseased "rats performed significantly better," and a " deficit in Tg rats was entirely reversed."

Those convinced that these murine (lab rodent) results can't possibly be predictive of human therapies of Anavex 3-71 against Alzheimer's disease will intelligently refrain from taking any position with AVXL shares based upon these new data. Well and good. Play it safe.

The rest of us, however, regard the findings of the transgenic rat study to be very predictive. We gleefully await consequent studies of Anavex 3-71 in humans with Alzheimer's. Our AVXL holdings are even more confidently held and accumulated.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News